Skip to main content

Table 4 Summary of humanistic burden evidence

From: Clinical, humanistic, and economic burden of chronic obstructive pulmonary disease (COPD) in Canada: a systematic review

References/study period Patient group N Scale Baseline score, mean (SD) Endpoint score, mean (SD) Change from baseline, mean (SD)
SF-36 score
 Appleton et al. [54]/November 1999–September 2001 Salmeterol 172 PH 36.5 (10.0) [N = 146] 37.1 (10.5) [N = 131] 0.3 (7.7) [N = 146]; mean difference vs placebo: 0.30; 95 % CI (−1.3, 1.9)
ME 49.3 (10.8) [N = 146] 50.0 (10.5) [N = 131] 1.1 (10.0) [N = 146]; mean difference vs placebo 0.03; 95 % CI (−1.9, 1.9)
Placebo 176 PH 36.1 (9.5) [N = 156] 36.8 (10.3) [N = 144] 0.1 (6.4) [N = 156]
ME 48.8 (11.0) [N = 156] 50.3 (10.6) [N = 144] 1.1 (9.1) [N = 156]
 HajGhanbari et al. [25]/study period not reported COPD patients 47 PH   35.2 (1.7) p = 0.000; AMD vs control: 16.9  
ME   42.0 (1.8) p = 0.000; AMD vs control: 12.8  
Healthy controls 47 PH   52.0 (1.3)  
ME   54.7 (1.30)  
 Moullec et al. [22]/Apr 2004–May 2006 Usual care 50 PH 37 (10)   
ME 47 (12)   
Intervention 60 PH 35 (8) p = 0.33   
ME 45 (12) p = 0.26   
 Lacasse et al. [55]/12 weeks Paroxetine 12 PH 18.6 (10.0)   
MH 53.1(23.2)   
Placebo 11 PH 19.0 (9.9); p = 0.9   
MH 58.0 (16.8); p = 0.4   
SGRQ scores
 Appleton et al. [54]/November 1999–September 2001 Salmeterol 172 T 46.2 (18.0) [N = 150] 41.6 (19.0) [N = 124] −2.9 (11.1) [N = 150]
S 59.6 (18.4) [N = 150 55.4 (19.7) [N = 124] −3.0 (15.8) [N = 150]
A 61.6 (21.9) [N = 150 53.3 (23.8) [N = 124] −5.9 (15.4) [N = 150]
I 33.5 (20.7) [N = 150] 30.6 (20.0) [N = 124] −1.2 (13.6) [N = 150]
Placebo 176 T 46.8 (16.6) [N = 157] 44.7 (18.6) [N = 139] −1.3 (10.3) [N = 157]
S 56.7 (19.6) [N = 157] 57.3 (21.6) [N = 139] 1.4 (15.5) [N = 157]
A 62.7 (18.9) [N = 157] 59.7 (22.4) [N = 139] −3.0 (15.0) [N = 157]
I 34.8 (18.9) [N = 157] 32.4 (20.3) [N = 139] −1.2 (11.5) [N = 157]
 Aaron et al. [56]/October 2003–January 2006 Tiotropium + placebo 156 T    −4.5
S    
A    
I    
Tiotropium + salmeterol 148 T    −6.3, p = 0.02
S    
A    
I    
Tiotropium + fluticasone/salmeterol 145 T    −8.6, p = 0.01
S    
A    
I    
 Chan et al. [20]/1 year Tiotropium 608 T   40.9  
S   44.4  
A    
I   28.5  
Placebo 305 T   43.7, p < 0.01  
S   49.3, p < 0.01  
A    
I   31.3, p < 0.01  
 Low et al. [27]/study period not reported Patient 67 T   
S   57.68 (24.71) [N = 66]; mean difference vs spouse: 1.73; p = 0.497  
A   70.42 (17.44) [N = 67]; mean difference vs spouse: −0.21; p = 0.771  
I   41.05 (22.83) [N = 66]; mean difference vs spouse: 5.6; p = 0.002  
Spouse 67 T   
S   59.41 (23.05) [N = 65]  
A   70.21 (18.72) [N = 66]  
I   47.29 (23.12) [N = 65]  
 Moullec et al. [22]/Apr 2004–May 2006 Usual care 50 T 49 (18)   
S 55 (16)   
A 66 (23)   
I 38 (20)   
Intervention 60 T 48 (16), p = 0.72   
S 54 (18), p = 0.74   
A 65 (20), p = 0.85   
I 37 (19), p = 0.72   
Chronic Respiratory Questionnaire Scores (CRQ)
 Lacasse et al. [55]/12 weeks Paroxetine 12 TG    
D 3.4 (0.9), p = 1.0   
E 3.5 (0.9), p = 0.8   
M 4.3 (1.0), p = 0.2   
F 3.6 (0.8), p = 0.3   
Placebo 11 TG   
D 3.4 (0.6)   
E 3.7 (1.0)   
M 4.9 (0.9)   
F 3.2 (1.1)   
 Bourbeau et al. [57] 6 months Budesonide 39 TG   
D 19.9 (6.2)   −1.8 (−3.9 to 0.2)
E 37.9 (6.9)   −1.9 (−5.3 to 1.4)
M 21.4 (4.2)   −0.5 (−2.4 to 1.4)
F 20.7 (3.6)   −3.0 (−4.9 to −1.2)
Placebo 40 TG  
D 19.5 (5.8)   −0.5 (−2.3 to −1.3)
E 36.2 (9.6)   −0.6 (−3.4 to 2.2)
M 21.7 (5.8)   −1.3 (−3.0 to 0.5)
F 19.3 (5.6)   −1.4 (−3.1 to 0.3)
 Leigh et al. [24]/4-week treatment period Overall population 40 TG 17.5 (3.6) Post-PB: 18.1 (3.5)
Post-BDN: 19.4 (3.4)
Post-PDN: 21.0 (3.4)
 
D 3.7 (1.0) Post-PB: 3.9 (0.9)
Post-BDN: 4.4 (1.1)
Post-PDN: 4.6 (1.3)
 
E    
M    
F    
Physical activity
 Vozoris et al. [23]/1994–2007 Obese COPD patients 858 Inactivitya; restricted activitya Inactive: 68 % patients
Activity restriction: 72 % patients
  
Non-obese COPD patients 2611 Inactivitya; restricted activitya Inactive: 60 % patients
Activity restriction: 60 % patients
  
 Rocker et al. [26]. Study period not reported Severe, stable COPD patients 8 Palliative performance scale Scores ranged from 50 to 70 %   
  1. A activity score, AMD absolute mean difference, BDN budesonide, D dyspnea, E emotional function, F fatigue, M mastery, ME Mental Health summary score, PB placebo, PDN prednisone, PH Physical Health summary score, S symptoms score, T total score, TG total (Global) score, I impact score
  2. aCanadian Fitness and Lifestyle Research Institute defined Inactivity as total daily energy expenditure value of < 1.5 kcal/kg/day; restricted activity: sometimes or often had difficulty with simple activities such as walking, climbing stairs, and bending